Combination therapies

Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PHILIPPAR, ULRIKE, PACKMAN, KATHRYN ELIZABETH, LIU, LIAN-ZHU, KWON, MINUL, LI, MING, DENG, XIANG-JUN, DARVILLE, NICOLAS FREDDY J, SUN, YU, LIU, YING-TAO, FU, LI-QIANG, GUTTKE, CHRISTINA DIANE, FANG, LIAO, VERHULST, TINNE ANN J, XU, YANPING, NG, ALICIA TEE FUAY, QUEROLLE, OLIVIER ALEXIS GEORGES, THURING, JOHANNES WILHELMUS J, CAI, WEI, PANDE, VINEET, DASKALAKIS, NIKKI, BHOGAL, BALPREET, DAI, XUEDONG, FERRANTE, LUCILLE ANGELA, PIETSCH, EVA CHRISTINE
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows:, wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.